ClearPoint Neuro, Inc.

NASDAQ:CLPT

Medical - Devices

Healthcare
$7.71 +5.30%

+$0.89 today

Market cap
$247.14M
Beta
1.31
P/E (TTM)
-18.0
EPS (TTM)
-$0.98
52W Low $8.27High $30.10

Volume 0.64M

Average 0.67M

CLPT EBITDA Margin

EBITDA as a percentage of revenue.

ClearPoint Neuro, Inc.NASDAQ: CLPT

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -58.1%

EBITDA Margin was -58.1% in Q1 FY2026, up 8.7 pp from a year earlier. On a trailing-twelve-month basis it was -58.2%, up 0.7 pp year over year. Over 3 fiscal years it widened by 19.4 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 1 analysts of -62.4% for the fiscal year ending Dec 2026, down from -56.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-58.1%+1.7 pp QoQ
Last fiscal yearDec 2025
-56.4%-2.2 pp YoY
LTMMar 2026
-58.2%+0.7 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+8.7 pp+7.5 pp-1.2 pp
1 year-2.2 pp-6.0 pp-3.7 pp
3 years+19.4 pp+22.3 pp+2.9 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-56.4%
Year-over-year change
-2.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CLPT compares with its peers on the latest reported figures

  • CLPT's LTM Mar 2026 EBITDA Margin of -58.2% is the 8th highest of the 9 companies compared; the peer median is -2.7%.
  • Its year-over-year change of +0.7 pp is the 5th highest of 9, against a peer median of +1.5 pp.
  • Over three fiscal years its change of +19.4 pp compares with a peer median of +1.0 pp.
CLPT Competitors Peer median
EBITDA Margin for CLPT and competitors
Company Period LTM level YoY 3-year change
OFIXOrthofix Medical Inc.LTM Mar 202611.5% +13.4 pp-6.1 pp
SNDLSNDL Inc.LTM Mar 20265.3% +10.5 pp+50.9 pp
VREXVarex Imaging CorporationLTM Apr 2026-0.7% -9.9 pp-12.9 pp
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-2.5% -5.1 pp+8.2 pp
SIBNSI-BONE, Inc.LTM Mar 2026-2.9% +7.7 pp+46.2 pp
AVNSAvanos Medical, Inc.LTM Mar 2026-3.0% +46.3 pp-16.1 pp
CTKBCytek Biosciences, Inc.LTM Mar 2026-10.8% -4.7 pp-14.4 pp
CLPTClearPoint Neuro, Inc.LTM Mar 2026-58.2% +0.7 pp+19.4 pp
LABStandard BioTools Inc.LTM Mar 2026-94.5% -30.2 pp+72.1 pp
CMPSCOMPASS Pathways plcFY2025— ——
Peer median (excluding CLPT) -2.7%+1.5 pp+1.0 pp

Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue16.3M20.55M23.96M31.39M36.97M
Cost of Revenue5.18M7.02M10.34M12.27M14.28M
Gross Profit11.12M13.53M13.61M19.12M22.69M
Gross Margin68.2%65.8%56.8%60.9%61.4%
Research & Development9.28M10.89M11.71M12.39M13.9M
Selling, General & Admin15.22M18.97M24.35M26.48M32.96M
Operating Expenses24.5M29.86M36.06M38.87M46.86M
Depreciation & Amortization692K777K1.46M1.9M2.24M
EBITDA(12.75M)(15.58M)(20.63M)(17.01M)(20.86M)
EBITDA Margin-78.2%-75.8%-86.1%-54.2%-56.4%
Operating Income(13.37M)(16.33M)(22.45M)(19.75M)(24.16M)
Operating Margin-82.1%-79.5%-93.7%-62.9%-65.4%
Interest Income00386K872K1.21M
Interest Expense973K81K002.39M
Other Income / Expenses(1.04M)(103K)357K832K(1.32M)
Income Before Tax(14.41M)(16.44M)(22.09M)(18.91M)(25.49M)
Pre-Tax Margin-88.4%-80.0%-92.2%-60.3%-68.9%
Income Tax Expense000055K
Net Income(14.41M)(16.44M)(22.09M)(18.91M)(25.54M)
Net Margin-88.4%-80.0%-92.2%-60.3%-69.1%
EPS (Basic)(0.69)(0.68)(0.90)(0.70)(0.90)
EPS (Diluted)(0.69)(0.68)(0.90)(0.70)(0.90)
Weighted Avg Shares20.73M24.18M24.61M27.03M28.32M
Weighted Avg Shares (Diluted)20.73M24.18M24.61M27.03M28.32M

ClearPoint Neuro, Inc.

NASDAQ:CLPT

Intrinsic Alpha fair value

Locked

Current Price

$7.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.